Breaking News, Collaborations & Alliances

Bavarian Nordic to Manufacture Additional Ebola Vaccines for Janssen

Deal valued at $13.9 million; manufacturing to begin this year.

By: Contract Pharma

Contract Pharma Staff

Bavarian Nordic A/S said it has entered into a new supply contract with Janssen Vaccines & Prevention B.V., part of the Janssen Pharmaceutical Companies of Johnson & Johnson valued at $13.9 million.   Bavarian Nordic will manufacture and deliver bulk drug substance of its MVA-BN Filo vaccine, which Janssen has licensed as part of its Ebola vaccine regimen.   Manufacturing of the vaccines will be initiated in 2020, supply will not occur until 2021.   “We are pleased to continue our strong...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters